Regression of Myocardial Steatosis by Nebivolol

Trial Profile

Regression of Myocardial Steatosis by Nebivolol

Phase of Trial: Phase 0

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Nebivolol (Primary)
  • Indications Heart failure; Hypertriglyceridaemia; Obesity
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Jul 2017 Status changed from not yet recruiting to completed.
    • 24 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top